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A B S T R A C TObjectives: Many jurisdictions are moving toward greater public
involvement in health technology assessment (HTA) processes. This
study aims to provide a broad, cross-sectional indication of the extent
and methods of public engagement in HTA, with a focus on which
public are engaged, by what mechanisms, and the purpose of public
engagement. Methods: An international Web-based survey of 217
organizations involved in HTA was undertaken. Contact e-mail
addresses for targeted organizations were identified from the Internet.
Results: Individuals from 39 (18%) of the contacted organizations
completed a survey. The majority (67%) of responding HTA organiza-
tions undertake public engagement activities, predominantly invol-
ving lay representatives of organized groups (81%), and to a lesser
extent individual patients/consumers (54%) or citizens/community
members (54%). For organizations undertaking public engagement,
mechanisms based on communication or consultation were the most
common, although some organizations have used or intend to use
participatory approaches, particularly the Citizens’ Jury (8%) orsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.09.011
rest: The author is not aware of any conflict of in
griffith.edu.au.
ndence to: Jennifer A. Whitty, Centre for Applied He
k, Queensland 4131, Australia.Consensus Council (20%) methods. Respondents identified with a
number of rationales and barriers for undertaking public engagement.
Conclusions: This survey provides further insight into the public
engagement approaches that are used by HTA organizations in
practice. In particular, it suggests a limited adoption of participatory
methods to date, and interest in the use of social media. Study
findings require further confirmation, due to limitations related to
survey response. There is considerable opportunity for further
research into pragmatic, robust, and meaningful approaches to public
engagement to strengthen HTA policy and decision-making frame-
works. An agenda for future research evolving from the survey
responses is proposed.
Keywords: decisionmaking, health policy, health technology assessment,
public engagement.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In an evolving era of patient-centered health care, many jurisdic-
tions are moving toward greater patient and public involvement
in health technology assessment (HTA) processes and decision
making [1,2]. The involvement of patients and the public in HTA
can provide a unique perspective, balancing the views of health
care professionals, service providers, and industry [3,4], promote
transparency and fair decision making [5], and legitimize the HTA
process [4,6]. HTA processes and decision making have a direct
impact on the choice of interventions and services that are
funded through scarce public health care resources and are
therefore available to be accessed by current or future patients.
HTA is fraught with challenging and sometimes conflicting social
values and ethical factors to be considered alongside technical
information and expertise to inform decision making [7], and the
decisions made as a result of HTA processes frequently apply
across a wide population.
This article reports the findings from an international Web-
based survey of organizations involved in HTA, with the aim ofexploring the extent and methods of public engagement in HTA
processes and decision making. The article starts by briefly
reviewing the literature on public engagement in the HTA setting.
The survey methods and scope are then described. The survey
results are presented, and the implications for HTA organizations
that may be developing public engagement processes or con-
sidering doing so are discussed, along with some potential
limitations of the study and recommended future research
directions.
What Do We Currently Know of Public Engagement
Experiences in the HTA Setting?
A number of frameworks for public engagement in HTA have
been proposed [2,8–15]. Some have concentrated largely on the
involvement of patients [10,11] or consumers [2,14], but others
have focused on involving the general public [9,11–13], of which
patients or consumers may be a subset. Aspects of public engage-
ment including who to involve, how to engage them, and for what
purpose have been identified as relevant considerations by severalSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
terest related to this research study.
alth Economics, School of Medicine, Griffith University, University
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 5 5 – 1 6 3156researchers [9,11]. Our knowledge of the application of these
frameworks or the extent of public involvement in HTA in practice,
however, is limited. A recent systematic review of the scientific
literature confirmed that there are few published examples of
experiences involving patients and the public in HTA [16]. Never-
theless, available studies do suggest an increasing interest in
involving the public in HTA processes and decision making,
particularly in the United Kingdom and Canada [16–18]. In an
early pilot study undertaken in 2001, Oliver et al. [17] found that
consumers were willing and able to play an active role in HTA
priority-setting processes, concluding that consumers made a
unique contribution to the HTA program (UK). The UK National
Institute for Health and Clinical Excellence has developed exten-
sive policy and processes around patient and public involvement
in HTA and has established a Citizens’ Council. The National
Institute for Health and Clinical Excellence’s Citizens’ Council was
arguably an innovative approach in the HTA setting at the time of
its inception in 2002 [19] and has been sustained over nearly a
decade to guide social value judgments in decision making [20].
More recently, there have been several published reports originat-
ing from Canada of the use of a Citizens’ Council or Citizens’ Jury
approach to engage the public to develop priority-setting criteria
[18] or explore the ‘‘reasonableness’’ of waiting for more evidence
before funding innovative health technologies [21]. Distinct from
the general public, patients with experience of a condition can
potentially provide useful insights into the lived experience for
specific technologies under assessment [4,22].
A Survey of International Practice
While there is some limited information available on public
engagement practices around HTA in the peer-reviewed litera-
ture, anecdotal observations and the recent review by Gagnon
et al. [16] suggest that organizational practices often occur
in policy environments and do not necessarily infiltrate the
peer-reviewed literature, remaining diverse and difficult to
synthesize. A previous survey of the International Network of
Agencies for Health Technology Assessment (INAHTA) member
organizations around the involvement of consumers in HTA was
undertaken in 2005 [23] and updated in November 2010 [24].
Findings suggest that approximately half of the organizations
responding involve consumers in some aspect of their programs,
with little change from 2005 to 2010. A recent summary of the
peer-reviewed and gray literature and Web sites of selected
organizations by Menon and Stafinski [22] explored the potential
roles for patients and the public in HTA and coverage decision
making, concluding that many of the HTA agencies in developed
countries have established mechanisms for seeking input from
patients or the public. While this survey and the review explore
the extent of public engagement [23,24] and approach to public
engagement by selected organizations [22], less is known about
the public engagement methods used across a broad range of
organizations.
This article reports the findings from an online international
cross-sectional survey of organizations involved with HTA pro-
cesses or decision making. Specifically, the survey aims to
provide further insights into three important considerations for
public engagement in HTA processes or decision making [9]:
which public are engaged, why they are engaged, and what
mechanisms are used for engagement?Methods
Ethical clearance was provided by the Griffith University Human
Research Ethics Committee. The online survey was undertaken
between September and November 2010. Organizations, groups,agencies, or committees (herein the term ‘‘organization’’ is used
to represent all these categories) involved in HTA processes or
decision making were identified from the Web by using a search
(September 2010) of membership lists, or in the case of ISPOR the
Directory of HTA Organizations, available at the Web sites of the
following umbrella organizations: INAHTA http://www.inahta.org/
 European Network for Health Technology Assessment
(EuNetHTA) http://www.eunethta.eu/Public/Home/
 International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) http://www.ispor.org/
 International Information Network on New and Emerging
Technologies (Euroscan) http://www.euroscan.org.uk/
To ensure a comprehensive coverage of HTA organizations, an
additional manual search was undertaken via Google to identify
contacts at further organizations indicated from the literature to
undertake HTA processes or decision making but not included
in the above Web sites [25–29]. A total of 264 e-mail contact
addresses were retrieved for a named contact where available,
otherwise a generic e-mail for the organization. Where more
than one e-mail address was available, all were retained to
maximize potential response. Two individuals contacted the
research team after the mailing of the original survey invite
and requested an additional survey invite. Therefore, a total of
266 e-mail invites were sent to e-mail addresses across 217 HTA
organizations. The e-mail invite briefly introduced the purpose
of the survey, provided a link for the completion of the survey,
and asked that the recipient forward the invite on to the most
appropriate person to complete the survey in his or her organiza-
tion, if this was not he or she. Two e-mail reminders were sent
to e-mail addresses that had not yet responded at fortnightly
intervals.
The survey was pilot tested in a group of university research-
ers with expertise in HTA prior to the main data collection. The
survey commenced by providing an information sheet, and some
background questions on the scope of the HTA organization
including a request to indicate whether the HTA organization
undertakes any form of public engagement activity. This was
followed by the main body of the survey, which consisted of a
number of questions around which public are engaged, what
mechanisms are used for engagement, the rationale for engaging
the public, an indication of whether the public engagement
activities have been evaluated, and challenges that had been
faced when engaging the public. Finally, respondents were given
the opportunity to provide feedback on the survey. A copy of the
survey instrument is provided in Appendix A in Supplemental
Materials found at doi: 10.1016/j.jval.2012.09.011.
The survey adopted Mitton et al’s definition of ‘‘public’’ [30]
and Rowe and Frewer’s typology of public engagement mechan-
isms [31]. Respondents were told that for the purpose of this
survey, ‘‘public’’ includes ordinary or lay citizens who are mem-
bers of the general public, members of social interest groups (but
not as health professionals), patients, or consumers [30] and
‘‘engagement’’ includes any process or attempt to support com-
munication, consultation, or participation with/by the public [31].
Furthermore, respondents were provided with definitions for
‘‘communication’’ (a one-way transfer of information, from the
HTA organization to the public), ‘‘consultation’’ (the provision of
information from the public to the HTA organization, but without
formal interaction or discussion), and ‘‘participation’’ (negotiation
and/or discussion with the public) [31].
Questions included in the survey instrument were selected
to ensure coverage of the study objectives and were informed by
the existing literature [9,30–32]. The majority of questions were
closed-ended (including individual and tabled multiple-choice
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expanded responses. Given that the aim of the survey was to
provide an overview of the extent and methods of public
engagement in HTA, analysis of closed-ended questions was
generally descriptive. Previous research suggests that the extent
to which the public want their preferences to be used to inform
decision making varies across different levels of priority setting
[33]. Therefore, an exploratory analysis tested for differences
between an organization’s highest level of operation and its
public engagement activities, with between-group differences
tested where stated using the chi-square, Fisher exact, or
Fisher-Freeman-Halton exact tests using ‘‘StatsDirect’’ (version
2.7.2 2008). Responses to the open-ended questions were grouped
and described by using a thematic approach [34].Results
A total of 40 completed survey responses were received, with
only one duplicate response received from any organization. For
the one duplicate response, both respondents answered consis-
tently and indicated that their organization did not undertake
any form of public engagement activity. Therefore, one of these
responses was excluded. In addition, six responses were received
indicating that the organization contacted was not involved in
HTA. Thus, the completed response rate was 18% (39 of 211
organizations). While the low response to this survey may
indicate potential sample bias, the recruitment strategy did cast
a ‘‘wide net’’ in an attempt to identify organizations that were
potentially relevant. Given the response rate, an analysis of
(non)responders was performed to assess bias by geographic
location and source of identification (Table 1). The analysis
suggests differences in response by geographical region and a
higher response from individuals at HTA organizations identified
via the INAHTAWeb site (P o 0.001). It was not feasible to expand
the (non)response analysis further, as other characteristics
including highest level of operation and involvement in deci-
sion/recommendations were collected as part of the survey and
therefore were not available for nonresponders. Furthermore, for
ethical reasons, it was considered inappropriate to identify the
responding organizations, especially as this would also infer
those that did not respond and potentially suggest the identityTable 1 – Comparison of responders and nonresponders by ge
Geographic location
International
Africa
America (including Canada and South America)
Asia
Australasia
Europe
Middle East
Subtotal
Identification source†
INAHTA
Other
Subtotal
INAHTA, International Network of Agencies for Health Technology Asse
* Fisher-Freeman Halton exact test, P ¼ 0.0006.
† w2 test, P o 0.0001.of individuals who participated in the survey. The responding
organizations are not named here for ethical reasons. They were,
however, disclosed to the journal’s editors so that they could
confirm that the sample broadly reflected HTA organizations
internationally.
The majority of respondents (29, 74%) indicated that their role
had direct input or responsibility for public engagement pro-
cesses at their organization. A summary of the characteristics of
the HTA organizations with which the respondents were asso-
ciated is provided in Table 2.
The HTA organizations were geographically diverse, with the
majority of organizations located in Europe (15, 38%), Australasia
(11, 28%), or the American continent (including Canada and
South America: 9, 23%). The majority of respondents indicated
that their organization operated at the national level or higher
(29, 74%). Organizations generally undertake more than one
‘‘task’’ related to HTA (horizon scanning, selection of tech-
nologies for assessment, undertaking HTA, funding or nonfunding
decisions/recommendations, postmarketing/funding surveillance),
with the mean number of tasks being 3  1.6. Twelve (31%) HTA
organizations made decisions or recommendations regarding
registration or market access for health technologies, 17 (44%)
made decisions or recommendations regarding the funding of
health technologies, and 22 (56%) made decisions or recommenda-
tions in either or both cases.
The majority (26, 67%) of the respondents indicated that their
organization undertakes some form of public engagement activ-
ity. There were no observed associations between whether or not
an organization undertakes public engagement activity and
whether they were responsible for making decisions or recom-
mendations around health technologies (w2 test, P ¼ 0.65) or their
highest level of operation (national or above vs. other, Fishers
exact test, P ¼ 0.70), although this lack of observed association
may be limited by the relatively small sample. Responses from
only the 26 individuals who indicated that their organization
undertakes some form of public engagement activity are
included in the remainder of the survey results.
Which Public Are Engaged?
The public engagement activities undertaken by the 26 organiza-
tions who reported some form of public engagement activity areographic location and identification source.
Total
invited
(N ¼ 211)
n (%)
Responders
(n ¼ 39)
Nonresponders
(n ¼ 172)
1 1 (100) 0 (0)
3 0 (0) 3 (100)
69 9 (13) 60 (87)
9 2 (22) 7 (78)
21 11 (52) 10 (48)
106 15 (14) 91 (86)
2 1 (50) 1 (50)
211 39 (18) 172 (82)
52 25 (48) 27 (52)
159 14 (9) 145 (91)
211 39 (18) 172 (82)
ssment.
Table 2 – Description of HTA organizations (N ¼ 39).
n (%)
Geographic location
International 1 (3)
America (including Canada and South
America)
9 (23)
Asia 2 (5)
Australasia 11 (28)
Europe 15 (38)
Middle East 1 (3)
Highest level of operation
Across more than one country 4 (10)
National 25 (64)
State or provincial 7 (18)
Regional 2 (5)
Local or hospital 1 (3)
Tasks undertaken by organization
Horizon scanning 18 (46)
Selecting technologies for assessment 25 (64)
Undertaking HTAs 31 (79)
Decisions/recommendations regarding
registration/market access for health
technologies (other than funding)
12 (31)
Decisions/recommendations regarding the
funding of health technologies
17 (44)
Surveillance after a positive registration,
access, or funding recommendation is made
15 (38)
Other 9 (23)
Organization undertakes any form of public
engagement activity
Yes 26 (67)
No 13 (33)
HTA, health technology assessment.
* Respondents selected all categories that apply; therefore,
numbers exceed 100%.
Table 3 – Public engagement activities (N ¼ 26).
n (%)
Who undertakes public engagement activities?
Your HTA organization itself 19 (73)
Contracted to a third party 6 (23)
Organization/company who requested the
technology to be funded/available
2 (8)
Other 6 (23)
Which categories of public does your HTA engage with?
Individual patients or consumers 14 (54)
Lay representatives of organized social
interest groups (e.g., health or consumer
groups)
21 (81)
Individual citizens or community members 14 (54)
Other 6 (23)
HTA, health technology assessment.
* Respondents selected all categories that apply; therefore,
numbers exceed 100%.
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undertake public engagement activities themselves, with some
(6, 23%) contracting a third party to undertake engagement either
instead of or in addition to themselves.
Most organizations that indicated that they undertake public
engagement activities (21, 81%) do so with lay representatives of
organized social interest groups (e.g., health or consumer groups),
and more than half of the respondents indicated that their
organization undertakes engagement activities with individual
patients/consumers or individual citizens/community members
(14, 54% for each category). Of the six (23%) organizations under-
taking engagement activities with other groups, respondents
indicated that these included having consumer representatives
on committees (2, 8% of respondents), industry, other govern-
ments, providers, politicians, health insurance companies, and
collection of patient perspectives through online blogs and
discussion forums.
Respondents were asked to indicate at which HTA stage their
organization engaged each category of the public (Table 4). For all
HTA stages, lay representatives of organized groups were the
most likely to be reported to be engaged. No organizations were
reported to engage these public groups when undertaking sur-
veillance after access or funding.
Respondents were provided with the opportunity to indicate
the engagement of the public in other HTA stages, or the
engagement of other public groups, than those listed in
Table 4. Other HTA tasks for which respondents reported theirorganizations engaged the public included funding research to
assess technologies (reported by one respondent). Other public
groups engaged included consumer representatives on commit-
tees, which were reported by up to two respondents to be used
for several HTA stages (undertaking HTAs, making access/fund-
ing decisions, surveillance after access/funding, and developing
HTA policy processes).
Mechanisms for Public Engagement
Respondents were shown a number of different mechanisms for
engaging the public, based on the approaches of communication,
consultation, and participation [31], and indicated whether their
HTA organization has used or plans to use this mechanism to
engage the public (Table 5). There were no observed associations
between an organization’s highest level of operation and the
absolute number of communication, consultation, or participa-
tion methods they had used (national or above 44, 47, and 6 vs.
below national 8, 10, and 0 for consultation, communication, and
participation methods, respectively; Fisher-Freeman-Halton exact
test, P ¼ 0.70); again, this lack of an observed association may be
limited by the relatively small sample.
Aweighted sum for each approach category (calculated as the
total sum of the number indicating each mechanism in that
category divided by the number of different mechanisms shown
for the category) is shown graphically in Figure 1. Overall, engage-
ment mechanisms based on communication or consultation were
reported to be the most commonly used, and mechanisms based
on participation the least commonly used. While a wide range of
communication and consultation mechanisms have been used,
participation methods have been almost entirely based on the
Citizens’ Jury or consensus conference approach (Table 5).
Rationale for Engaging the Public
Respondents were asked to indicate what their HTA organization
hoped to achieve by engaging the public (Table 6). The majority
indicated that public engagement was undertaken to inform
policy and procedures around HTA (19, 73%) or value judgments
for decision making (20, 77%). Informing specific HTA decisions
(15, 58%) and informing the public of decisions and their basis
(14, 54%) also featured as important rationale for engaging the
public.
The majority of respondents (18, 69%) indicated that their
organization integrated the findings of public engagement activ-
ities with other forms of evidence (e.g., scientific evidence) to
Table 4 – Category of the public engaged at each HTA stage.
HTA stage Number of organizations engaging (% of 26)
Patients or
consumers
Lay representatives of
organized groups
Individual citizens/
community members
Horizon scanning 2 (8) 3 (12) 2 (8)
Selecting technologies for assessment 4 (15) 6 (23) 2 (8)
Undertaking HTAs 4 (15) 7 (27) 3 (12)
Decisions/recommendations regarding
access/funding
1 (4) 3 (12) 0
Surveillance after access/funding 0 0 0
Developing HTA policy/processes 4 (15) 8 (31) 6 (23)
HTA, health technology assessment.
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(19%) indicated that their organization did not integrate the
findings, and three (12%) indicated they did not know whether
this was the case. Those who indicated that their organization
integrated the findings broadly suggested that this was achieved
through the following:T
C
C
C
C
P
P
*Consumer representatives on committees who participate in
decision making; Written summary or narrative of consumer perspectives
derived through, for example, patient interviews, statements
on the impact of an illness on consumers, Internet consulta-
tion, or social media including Web blogs, which are providedable 5 – Approaches to engaging the public.
No plans to
use
ommunication
Information broadcasts/publicity (e.g., via
media, television)
10 (38)
Public hearing or meeting 9 (35)
Drop-in center 21 (81)
Internet information/Web site 1 (4)
Telephone information line 14 (54)
ommunication: Weighted sum and
percentage
11 (42)
onsultation
Opinion poll/survey 11 (42)
Telepolling or voting by telephone 23 (88)
Referendum 21 (81)
Consultation document 10 (38)
Electronic consultation/interactive Web site 8 (31)
Focus group 6 (23)
Study circle or open space 18 (69)
Standing citizens’ advisory panel 14 (54)
onsultation: Weighted sum and percentage 13.9 (53)
articipation
Citizens’ jury 21 (81)
Consensus conference 15 (58)
Negotiated rule making or task force 20 (77)
Deliberative poll or planning cell 21 (81)
Town meeting with voting 23 (88)
articipation: Weighted sum and percentage 20 (77)
Weighted sum for each category calculated as the total sum of the num
number of different mechanisms shown for the category.to committees for consideration alongside other evidence
when making decisions; and Consumer input to guide research direction or systematic
review protocols, for example, via Internet questionnaires,
project steering committees, or issues raised by public advi-
sory committees.
Some respondents (11, 42%) indicated that their organization
had evaluated their public engagement activities. The majority
(14, 54%), however, indicated that they had not, with 1 (4%)
indicating not knowing whether this was the case. Those who
provided details specified that much of the work evaluating
public engagement is newly commenced or ongoing. Broadly,n (%)
Plan to
use
UsedZ once Don’t
know
4 (15) 7 (27) 5 (19)
2 (8) 13 (50) 2 (8)
1 (4) 1 (4) 3 (12)
2 (8) 23 (88) 0 (0)
1 (4) 8 (31) 3 (12)
2 (8) 10.4 (40) 2.6 (10)
3 (12) 8 (31) 4 (15)
0 (0) 2 (8) 1 (4)
1 (4) 1 (4) 3 (12)
1 (4) 13 (50) 2 (8)
5 (19) 10 (38) 3 (12)
2 (8) 13 (50) 5 (19)
0 (0) 3 (12) 5 (19)
2 (8) 7 (27) 3 (12)
1.8 (7) 7.1 (27) 3.3 (13)
0 (0) 2 (8) 3 (12)
2 (8) 3 (12) 6 (23)
0 (0) 1 (4) 5 (19)
0 (0) 0 (0) 5 (19)
0 (0) 0 (0) 3 (12)
0.4 (2) 1.2 (5) 4.4 (17)
ber indicating each mechanism in that category divided by the
Fig. 1 – Weighted sum of responses for each overall
approach category.
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their public engagement activities via approaches including
consultation with consumers or consumer organizations, evalu-
ating the impact of an HTA report on the practice and uptake of
information materials, and assessing the influence of public
engagement on commissioned research.
Challenges and Barriers to Engaging the Public
Seventeen (65%) of the respondents described challenges they
were aware their organization had faced related to engaging the
public in HTA processes and decision making. Challenges to
engagement identified by respondents included the potential
tension between social and scientific considerations, and practi-
calities around engaging patients and dissemination of informa-
tion. Timeliness featured prominently, with respondents
indicating a mismatch between the demand for timely HTA and
the time required to undertake high-quality public engagement.
A lack of expertise for undertaking qualitative research was
identified as a challenge, suggesting that in the same way that
the interpretation of technical material relies on and may be
challenged by a lack of scientific expertise, public engagement
may also be hampered by a lack of appropriate expertise.
Challenges around who to engage, who those engaged ‘‘repre-
sent,’’ potential biases or conflict of interest, and the difficulty of
engaging an ‘‘uninformed’’ public were also identified.Table 6 – Rationale for undertaking public engagement.
Aim n (%)
Inform policy and procedures around HTA 19 (73)
Inform value judgments for decision making 20 (77)
Inform specific HTA decisions 15 (58)
Inform the public of decisions and their rationale 14 (54)
Other† 4 (15)
HTA, health technology assessment.
* Respondents selected all categories that apply; therefore,
numbers exceed 100%.
† Other rationale included to identify new technologies of interest
to patient groups; gain patient group opinion of potential
benefits of emerging technologies; ensure the quality of the
HTA and enforce implementation; disseminate information; and
inform policy and procedures around non-HTA decisions.Several respondents indicated a lack of HTA and patient
organization resources to support public engagement as a poten-
tial barrier. Respondents were asked, if possible, to provide an
estimate of the total amount of money that their HTA organiza-
tion spent on public engagement activities in the last year;
however, the majority (18, 69%) were not able and/or willing to
do so. Of the eight who answered this question, three (12%)
stated that they did not know the amount, two (8%) indicated
that there was no expenditure on public engagement specifically,
and three (12%) indicated a figure but interpretation of the
amounts provided was not clear within the context of the
question and respondent feedback.Discussion
This international survey sought to explore the extent to which
HTA organizations engage the public in their processes and
decision making, which public groups they engage, and in
particular the methods used and rationale for engagement. The
findings suggest that across a broad range of HTA organizations,
the majority (67% of the 39 responders) currently undertake some
form of public engagement activity. However, the low response
from the survey suggests that some selection bias may be present
and limits the conclusions that can be drawn from this study.
Stafinski et al. [35] critically reviewed actual HTA decision-
making processes and subsequently explored the role of patient
and public participation in these processes [22], reporting that 11
of 20 included countries and all four province/states involved
patients or the public in HTA decision-making processes to some
extent. Responses to the current survey were received from
individuals associated with five national and one provincial/state
organization across four countries included in the Stafinski et al.
review, reflecting approximately one fifth of the decision-making
processes outlined by the review authors. However, approxi-
mately half the organizations in the current survey reported
being responsible for making decisions or recommendations,
suggesting that the current survey captures to some extent a
different set of decision-making processes to the previous review.
Sixteen of the 33 organizations responding to the 2010 INAHTA
survey [24] are represented in the current survey sample,
although 25 of the responders were INAHTA members, suggest-
ing that the current survey also captures an overlapping but
different group of INAHTA member organizations to the previous
INAHTA survey. Therefore, while the current survey includes
response from some of the key organizations involved in the
assessment and recommendations around technologies and
extends our understanding of public and patient engagement, it
also highlights the challenges with capturing a complete and
defined sample of relevant organizations and processes.
While findings related to the extent of public engagement and
the public groups that are engaged are useful insights from this
survey and are largely aligned with previous studies [22–24], little
previous research has attempted to summarize the public
engagement methods used by HTA organizations to undertake
public engagement across a large cross-sectional sample. The
findings of this survey suggest that public engagement mechan-
isms used by HTA organizations predominantly occur via one-
way transfer of information either from the HTA organization to
the public (communication) or vice versa (consultation) [31].
These methods represent relatively low-level involvement,
according to Arnstein’s Ladder of Citizen Participation [36].
To date, despite indications of a growing interest in the use
of participatory methods for public engagement in priority set-
ting [30], most notably deliberative approaches to public engage-
ment and some published examples [9,18,19,30], the findings
suggest that methods based on participation may not have been
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 5 5 – 1 6 3 161widely adopted in the HTA setting. Observations from the survey
responses suggest that there is interest in engaging the public
through social media such as Web blogs and discussion forums.
This approach has been reported in the literature in an attempt
to develop lower resource methods for consultation [37], and the
use of social media may represent a developing mechanism for
engaging the public and/or patients in the HTA setting. An
exploration of the underlying reasons for organizational choice
between the different engagement mechanisms is an area for
future research.
The findings suggest that those organizations undertaking
public engagement do so for a range of reasons, with evidence of
a desire to achieve process-orientated goals, instrumental goals,
and goals related to knowledge and capacity [9]. For organiza-
tions reporting public engagement, most respondents indicated
that their organization has recognized a need to involve the
public in informing policy and procedures around HTA, including
the development of value judgments to inform decision making.
Many organizations also use public engagement to inform spe-
cific HTA decisions or to inform the public of decisions and their
rationale. While the rationale for undertaking public engagement
is consistent with that reported previously [9], the survey did not
explore the reasons why some organizations (33% in the survey)
do not undertake public engagement, and this would be an
interesting area for further research.
A number of respondents to the survey reported that their
organization had evaluated their public engagement activity,
although there was a general trend for these evaluations to
be newly initiated or not yet complete. Previous reviews of
public engagement in HTA or more broadly in priority setting
found few reports of the formal evaluation of public engagement
processes [16,22,30], with a prominent exception in the HTA
setting of the evaluation of the National Institute for Health
and Clinical Excellence Citizens’ Council [19]. The relatively
recent nature of the evaluative processes reported by survey
respondents suggests the potential for a greater focus on the
evaluation of the impact and outcomes of engagement processes
over the next few years.
One prominent challenge to engaging the public identified by
respondents was the mismatch between the time needed to
undertake high-quality and robust public engagement activities
and the timeliness required for HTA reports and decision making.
Respondents also identified challenges around the question of who
to recruit, who they represent, and whether they are informed, and
similar challenges associated with engaging the public have been
suggested by others [11,16]. While some of these barriers may be
overcome by the careful selection of engagement methods (e.g., the
Citizens’ Jury approach may be considered desirable because it
uses an unbiased yet informed sample of the general public [18]) orAvenues for future research into public engagement a
Why do some HTA organisations report that they
this a philosophical position, or is a lack of engag
Why and in what circumstances do organisations
another?
Do different levels of HTA organisation use differe
To what extent do HTA organisations synthesise 
or quantify patient or public preferences to inform
What are the potential role, benefits and disadvan
engagement, such as the use of social media? 
How can we synthesise the published literature a
engagement in the HTA setting, to provide a mor
this area? 
Fig. 2 – Avenues for future research. Hby novel approaches to public engagement [37], others may be
overcome only by regulatory and/or policy support.Limitations
The response rate for this survey (18%) was substantially lower
than the approximately 90% response rate achieved by previous
INAHTA surveys [23,24]. The response rate for the subgroup of
invited participants who were INAHTA members (48%, Table 1)
was more favorable. It is only possible to speculate as to why the
survey achieved a relatively low response; however, it seems
possible that the recruitment strategy lacked specificity. Six
responses were received indicating that the organization con-
tacted was not involved in HTA, five of which were from contacts
identified from sources other than INAHTA, which may suggest
that this might be the case for other organizations and partly
explain the response rate. One respondent went to considerable
effort to request a copy of the survey prior to completion, to
enable the organization to identify the best respondent. In future,
the inclusion of a hardcopy of a Web-based survey with the
invitation to participate might provide reassurance and assisted
targeting, thereby potentially increasing response. Furthermore,
a more selective recruitment approach, such as targeting INAHTA
members (who had the highest response rate in this study) and
using a snowballing method to extend an invitation to organiza-
tions undertaking HTA who are not INAHTA members, sending
invites through ISPOR regional chapters, or recruiting through an
HTA conference such as that held annually by the HTA Interna-
tional Society, may improve participation. A relatively high
response was also observed from individuals at organizations
based in Australasia (Table 1). It is possible that those based
in Australasia were more likely to respond given that the invite
came from a research institution in Australia.
The survey findings rely on the accuracy of the responses
provided by individuals associated with each organization, and
while the individual was often a person in a position with
responsibility for public engagement processes within that orga-
nization, this was not always the case. Furthermore, the selection
strategy may not have identified all relevant HTA organizations.
The survey instrument attempted to be comprehensive in pro-
viding definitions for respondents, and included open as well
as closed questions, to provide respondents with maximal
opportunity to comment on item responses. Nevertheless, it is
possible that some questions may have been interpreted incon-
sistently by respondents. In considering these factors and the
potential for response bias, it is not possible to be sure how
representative the survey is of the HTA setting internationally
and the findings of this survey should be viewed as indicative.pproaches in the HTA setting: 
 do not undertake public engagement activity? Is 
ement based on pragmatic barriers?
 choose one engagement mechanism over 
nt public engagement mechanisms? 
the literature on patient needs and perspectives 
 HTA processes and decision-making? 
tages of novel approaches to public 
nd experiences from actual examples of public 
e complete picture of development and activity in 
TA, health technology assessment.
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practices, which is difficult to synthesize from other sources.
Some researchers have advocated a vision for the future
of patient-based HTA, driven by the paradigms of patient empow-
erment and patient-centered care, in which the needs, desires,
and preferences of patients would be key considerations in HTA
processes and decision making [4,8]. They argue that HTA can be
strengthened by gathering robust scientific evidence on patient
perspectives and preferences, using research methods such as a
systematic synthesis of the qualitative literature and quantitative
measures of preferences (e.g., via time trade-off, standard gam-
ble, contingent valuation, or discrete choice techniques), to
inform HTA decision making. The current survey did not speci-
fically explore the use of research and scientific evidence in this
way, but rather it provides a cross-sectional indication of the
extent and methods of public engagement in HTA internationally.
Furthermore, the quality-adjusted life-year is a commonly
recommended measure in economic evaluation and is used to
inform HTA in many jurisdictions [38–41]; the quality-adjusted
life-year is estimated by using public preferences for different
health states. Although an assessment of the extent to which
HTA organizations synthesize the literature on patient needs and
perspectives or quantify patient or public preferences per se to
inform HTA decision making was not considered in this study,
this would be an interesting avenue for future research.
Implications for Policy and Research
In their recent systematic review, Gagnon et al. concluded that
‘‘There are few published examples of experiences involving
patients and the public in HTA,’’ identifying the need to ‘‘develop
more systematic approaches to considering patients’ and the
public’s perspectives in HTA’’ [16]. The implications of the survey
findings support those of Gagnon et al.: HTA organizations should
be encouraged to publish narratives of their experiences with
public engagement, to support the development of systematic yet
pragmatic approaches and frameworks for doing so. Policy-
makers need to ensure that sufficient resources, both monetary
and skill base, are available to support the development and
evaluation of robust public engagement frameworks for HTA
processes and decision making. The findings also suggest a
number of avenues for future research, which have been dis-
cussed throughout this article and are summarized in Figure 2.Conclusions
The findings of this international survey provide some further
insights into the approaches that are used by HTA organizations
to engage the public in practice, including which public are
engaged, by what mechanism, and for what purpose. Of parti-
cular note, the findings suggest a limited adoption of participa-
tory methods to date, and an apparent interest in the use of
social media. There is evidence of ongoing but unreported
evaluation of public engagement activity in the HTA setting,
which may provide further insight into the impact of public
engagement. Study findings require further confirmation, due to
limitations related to survey response. There is considerable
opportunity for further research into pragmatic, robust, and
meaningful approaches to public engagement to strengthen
HTA policy and decision-making frameworks (Figure 2).Acknowledgments
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